News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
398,353 Results
Type
Article (32071)
Company Profile (61)
Press Release (366221)
Multimedia
Podcasts (41)
Webinars (5)
Section
Business (112967)
Career Advice (1323)
Deals (24064)
Drug Delivery (94)
Drug Development (59747)
Employer Resources (104)
FDA (9956)
Job Trends (9104)
News (211744)
Policy (25537)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (1)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (1)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
2026 BioCapital Standard (1)
2026 Bio NC Standard (1)
2026 Genetown Standard (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (1846)
Accelerated approval (4)
Adcomms (20)
Allergies (67)
Alliances (42315)
ALS (58)
Alzheimer's disease (1108)
Antibody-drug conjugate (ADC) (98)
Approvals (9949)
Artificial intelligence (160)
Autoimmune disease (17)
Automation (7)
Bankruptcy (237)
Best Places to Work (7711)
BIOSECURE Act (16)
Biosimilars (83)
Biotechnology (45)
Bladder cancer (49)
Brain cancer (27)
Breast cancer (187)
Cancer (1613)
Cardiovascular disease (127)
Career advice (1114)
Career pathing (20)
CAR-T (106)
Cell therapy (293)
Cervical cancer (16)
Clinical research (48243)
Collaboration (682)
Compensation (430)
Complete response letters (19)
COVID-19 (2477)
CRISPR (30)
C-suite (113)
Cystic fibrosis (58)
Data (1509)
Decentralized trials (1)
Denatured (9)
Depression (35)
Diabetes (216)
Diagnostics (3577)
Digital health (10)
Diversity (4)
Diversity, equity & inclusion (33)
Drug discovery (88)
Drug pricing (97)
Drug shortages (28)
Duchenne muscular dystrophy (83)
Earnings (40420)
Editorial (36)
Employer branding (13)
Employer resources (94)
Events (45980)
Executive appointments (320)
FDA (10802)
Featured Employer (18)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (479)
Gene editing (74)
Generative AI (13)
Gene therapy (231)
GLP-1 (692)
Government (4101)
Grass and pollen (5)
Guidances (35)
Healthcare (11449)
Huntington's disease (19)
IgA nephropathy (21)
Immunology and inflammation (86)
Indications (23)
Infectious disease (2618)
Inflammatory bowel disease (78)
Inflation Reduction Act (7)
Influenza (52)
Intellectual property (70)
Interviews (231)
IPO (10454)
IRA (40)
Job creations (1749)
Job search strategy (956)
Kidney cancer (7)
Labor market (18)
Layoffs (280)
Leadership (9)
Legal (7061)
Liver cancer (52)
Lung cancer (233)
Lymphoma (108)
Machine learning (6)
Management (32)
Manufacturing (223)
MASH (56)
Medical device (5925)
Medtech (5926)
Mergers & acquisitions (14021)
Metabolic disorders (594)
Multiple sclerosis (52)
NASH (20)
Neurodegenerative disease (69)
Neuropsychiatric disorders (25)
Neuroscience (1495)
NextGen: Class of 2025 (3672)
Non-profit (2777)
Northern California (1636)
Now hiring (5)
Obesity (338)
Opinion (194)
Ovarian cancer (53)
Pain (49)
Pancreatic cancer (67)
Parkinson's disease (114)
Partnered (13)
Patents (162)
Patient recruitment (59)
Peanut (38)
People (24929)
Pharmaceutical (18)
Pharmacy benefit managers (10)
Phase I (14582)
Phase II (20957)
Phase III (16998)
Pipeline (892)
Policy (130)
Postmarket research (1846)
Preclinical (6054)
Press Release (28)
Prostate cancer (78)
Psychedelics (28)
Radiopharmaceuticals (205)
Rare diseases (269)
Real estate (2582)
Recruiting (44)
Regulatory (16150)
Reports (22)
Research institute (1599)
Resumes & cover letters (195)
Rett syndrome (3)
RNA editing (3)
RSV (47)
Schizophrenia (60)
Series A (79)
Series B (42)
Service/supplier (4)
Sickle cell disease (38)
Southern California (1340)
Special edition (5)
Spinal muscular atrophy (137)
Sponsored (19)
Startups (1891)
State (1)
Stomach cancer (11)
Supply chain (54)
Tariffs (27)
The Weekly (31)
United States (13295)
Vaccines (708)
Venture capitalists (28)
Weight loss (248)
Women's health (13)
Worklife (10)
Date
Today (72)
Last 7 days (398)
Last 30 days (1590)
Last 365 days (21029)
2025 (6372)
2024 (22419)
2023 (25346)
2022 (33453)
2021 (35972)
2020 (34115)
2019 (27931)
2018 (21250)
2017 (20205)
2016 (18713)
2015 (21511)
2014 (15961)
2013 (12888)
2012 (13628)
2011 (14406)
2010 (13083)
Location
Africa (570)
Alabama (30)
Alaska (3)
Arizona (90)
Arkansas (5)
Asia (25947)
Australia (4677)
California (3581)
Canada (1212)
China (356)
Colorado (151)
Connecticut (156)
Delaware (100)
Europe (62246)
Florida (540)
Georgia (125)
Hawaii (1)
Idaho (28)
Illinois (290)
India (23)
Indiana (191)
Iowa (8)
Japan (121)
Kansas (61)
Kentucky (15)
Louisiana (10)
Maine (28)
Maryland (641)
Massachusetts (2571)
Michigan (101)
Minnesota (139)
Mississippi (1)
Missouri (50)
Montana (20)
Nebraska (10)
Nevada (36)
New Hampshire (20)
New Jersey (1130)
New Mexico (15)
New York (1078)
North Carolina (507)
North Dakota (4)
Northern California (1636)
Ohio (112)
Oklahoma (6)
Oregon (10)
Pennsylvania (785)
Puerto Rico (5)
Rhode Island (13)
South America (797)
South Carolina (11)
South Dakota (1)
Southern California (1340)
Tennessee (52)
Texas (439)
Utah (85)
Virginia (91)
Washington D.C. (37)
Washington State (307)
West Virginia (2)
Wisconsin (27)
398,353 Results for "epigenomics ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Epigenomics Market Size Expected to Reach USD 69.70 Billion By 2034
February 27, 2025
·
1 min read
Deals
New Day Diagnostics Announces Approval of Purchase Agreement by Epigenomics’ AG Extraordinary General Meeting
New Day Diagnostics is pleased to announce that the Extraordinary General Meeting of Epigenomics AG (Frankfurt General Standard: ECX1), a molecular diagnostics company focused on blood testing for the early detection of cancer, has approved the acquisition agreement between the two organizations.
September 14, 2023
·
3 min read
Deals
New Day Diagnostics LLC Reinforces Commitment to Early Cancer Intervention with Its intention to Acquire the Assets of Epigenomics AG
New Day Diagnostics LLC is pleased to announce that it has entered into an asset purchase agreement with Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer.
July 24, 2023
·
4 min read
Press Releases
Bacteria in Our Aging Guts Can Elevate Risk of Leukemia
April 24, 2025
·
7 min read
Press Releases
Additional Member for the Board of Directors of Bachem Holding AG
April 3, 2025
·
3 min read
Press Releases
Luminopia Announces FDA Clearance for Patients with Amblyopia Aged 8 to 12 Years
April 22, 2025
·
5 min read
Press Releases
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
January 13, 2025
·
3 min read
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Press Releases
Compremium AG Appoints Dr. Kolaleh Eskandanian to Lead New Division of Pediatrics and Special Populations
April 24, 2025
·
4 min read
Genetown
Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)
Modalis Therapeutics Corporation, a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the preprint paper titled “Efficient and durable gene activation by Cas9-mediated epigenome editing in vivo” on bioRxiv.
May 7, 2024
·
4 min read
1 of 39,836
Next
